Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

Fig. 3

BET Bromodomain Inhibition Augments Susceptibility to CD8 T Cell-Mediated Cytotoxicity. a Specific lysis of JQ1 pretreated MC38OVA cells by OT-I CD8 cells. Specific lysis calculated as (% Lysis - %Nonspecific Lysis) / (% Maximum lysis - % nonspecific lysis). Significance compared to DMSO group. N = 3 wells / iteration, repeated × 3. b Percent specific lysis of pretreated MC38OVA cells in the absence of OT-I CD8 cells. Significance calculated using Tukey’s multiple comparisons test through 2-way Repeated Measures ANOVA . * p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. Error bars = standard deviation. c Summary of flow cytometry data for PD-L1 staining in ex-vivo MC38OVA tumors, gated on Live CD45 cells. N = 5 mice / iteration, repeated × 3. d Summary of flow cytometry data for OVA Tetramer staining in ex-vivo MC38OVA tumors gated on Live CD45+TCRb+CD4CD8+ cells. N = 5 mice / iteration, repeated × 3

Back to article page